🚀 VC round data is live in beta, check it out!
Laboratorios Rovi Valuation Multiples
Discover revenue and EBITDA valuation multiples for Laboratorios Rovi and similar public comparables like Asymchem Laboratories, Apogee Therapeutics, GSK India, Alkermes and more.
Laboratorios Rovi Overview
About Laboratorios Rovi
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
Founded
1946
HQ
Employees
2.2K
Website
Financials (LTM)
EV
$5B
Laboratorios Rovi Financials
Laboratorios Rovi reported last 12-month revenue of $888M and EBITDA of $254M.
In the same LTM period, Laboratorios Rovi generated $601M in gross profit, $254M in EBITDA, and $167M in net income.
Revenue (LTM)
Laboratorios Rovi P&L
In the most recent fiscal year, Laboratorios Rovi reported revenue of $876M and EBITDA of $238M.
Laboratorios Rovi expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $888M | XXX | $876M | XXX | XXX | XXX |
| Gross Profit | $601M | XXX | $548M | XXX | XXX | XXX |
| Gross Margin | 68% | XXX | 63% | XXX | XXX | XXX |
| EBITDA | $254M | XXX | $238M | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 27% | XXX | XXX | XXX |
| EBIT Margin | 24% | XXX | 24% | XXX | XXX | XXX |
| Net Profit | $167M | XXX | $157M | XXX | XXX | XXX |
| Net Margin | 19% | XXX | 18% | XXX | XXX | XXX |
| Net Debt | — | — | $82M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Laboratorios Rovi Stock Performance
Laboratorios Rovi has current market cap of $5B, and enterprise value of $5B.
Market Cap Evolution
Laboratorios Rovi's stock price is $95.50.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5B | $5B | -0.7% | XXX | XXX | XXX | $3.07 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialLaboratorios Rovi Valuation Multiples
Laboratorios Rovi trades at 5.6x EV/Revenue multiple, and 19.6x EV/EBITDA.
EV / Revenue (LTM)
Laboratorios Rovi Financial Valuation Multiples
As of March 21, 2026, Laboratorios Rovi has market cap of $5B and EV of $5B.
Equity research analysts estimate Laboratorios Rovi's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Laboratorios Rovi has a P/E ratio of 29.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV/Revenue | 5.6x | XXX | 5.7x | XXX | XXX | XXX |
| EV/EBITDA | 19.6x | XXX | 20.9x | XXX | XXX | XXX |
| EV/EBIT | 22.9x | XXX | 24.1x | XXX | XXX | XXX |
| EV/Gross Profit | 8.3x | XXX | 9.1x | XXX | XXX | XXX |
| P/E | 29.3x | XXX | 31.1x | XXX | XXX | XXX |
| EV/FCF | 36.6x | XXX | 57.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Laboratorios Rovi Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Laboratorios Rovi Margins & Growth Rates
Laboratorios Rovi's revenue in the last 12 month grew by 11%.
Laboratorios Rovi's revenue per employee in the last FY averaged $0.4M.
Laboratorios Rovi's rule of 40 is 39% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Laboratorios Rovi's rule of X is 55% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Laboratorios Rovi Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | (0%) | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | 18% | XXX | 4% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 39% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 55% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 39% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Laboratorios Rovi Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Asymchem Laboratories | XXX | XXX | XXX | XXX | XXX | XXX |
| Apogee Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| Alkermes | XXX | XXX | XXX | XXX | XXX | XXX |
| Beijing Tiantan | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Laboratorios Rovi M&A Activity
Laboratorios Rovi acquired XXX companies to date.
Last acquisition by Laboratorios Rovi was on XXXXXXXX, XXXXX. Laboratorios Rovi acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Laboratorios Rovi
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialLaboratorios Rovi Investment Activity
Laboratorios Rovi invested in XXX companies to date.
Laboratorios Rovi made its latest investment on XXXXXXXX, XXXXX. Laboratorios Rovi invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Laboratorios Rovi
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Laboratorios Rovi
| When was Laboratorios Rovi founded? | Laboratorios Rovi was founded in 1946. |
| Where is Laboratorios Rovi headquartered? | Laboratorios Rovi is headquartered in Spain. |
| How many employees does Laboratorios Rovi have? | As of today, Laboratorios Rovi has over 2K employees. |
| Who is the CEO of Laboratorios Rovi? | Laboratorios Rovi's CEO is Juan Lopez-Belmonte Encina. |
| Is Laboratorios Rovi publicly listed? | Yes, Laboratorios Rovi is a public company listed on Bolsa de Madrid. |
| What is the stock symbol of Laboratorios Rovi? | Laboratorios Rovi trades under ROVI ticker. |
| When did Laboratorios Rovi go public? | Laboratorios Rovi went public in 2007. |
| Who are competitors of Laboratorios Rovi? | Laboratorios Rovi main competitors are Asymchem Laboratories, Apogee Therapeutics, GSK India, Alkermes. |
| What is the current market cap of Laboratorios Rovi? | Laboratorios Rovi's current market cap is $5B. |
| What is the current revenue of Laboratorios Rovi? | Laboratorios Rovi's last 12 months revenue is $888M. |
| What is the current revenue growth of Laboratorios Rovi? | Laboratorios Rovi revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Laboratorios Rovi? | Current revenue multiple of Laboratorios Rovi is 5.6x. |
| Is Laboratorios Rovi profitable? | Yes, Laboratorios Rovi is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Laboratorios Rovi? | Laboratorios Rovi's last 12 months EBITDA is $254M. |
| What is Laboratorios Rovi's EBITDA margin? | Laboratorios Rovi's last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of Laboratorios Rovi? | Current EBITDA multiple of Laboratorios Rovi is 19.6x. |
| What is the current FCF of Laboratorios Rovi? | Laboratorios Rovi's last 12 months FCF is $136M. |
| What is Laboratorios Rovi's FCF margin? | Laboratorios Rovi's last 12 months FCF margin is 15%. |
| What is the current EV/FCF multiple of Laboratorios Rovi? | Current FCF multiple of Laboratorios Rovi is 36.6x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.